Yelak Biru/LinkedIn
Jun 16, 2025, 16:24
Yelak Biru: Anito-Cel Drives Durable Responses in R/R Multiple Myeloma
Yelak Biru, President and Chief Executive Officer at International Myeloma Foundation, posted on X:
“Congratulations Dr. Kaur on this iMMagine-1 study result and presentation at EHA 2025
‘Anito-cel utilizes a novel, synthetic antigen-binding domain called the D-Domain, which allows for high transduction efficiency, CAR positivity, and CAR density on the T-cell surface. Coupled with a fast off rate and ability to detach from the BCMA target, [this provides] us with a safe and efficacious product,’ lead study author Gurbakhash Kaur said during the presentation.
-
Anito-cel achieved a 97% overall response rate in relapsed/refractory multiple myeloma patients with at least three prior therapies, with a stringent complete response rate of 68%.
-
The novel D-Domain in anito-cel enhances transduction efficiency and safety, contributing to its efficacy in the iMMagine-1 trial.
-
Safety data showed manageable cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome, with most cases resolving quickly.
-
Anito-cel is being further evaluated in the phase 3 iMMagine-3 trial against standard-of-care therapy for relapsed/refractory multiple myeloma.”
Title: Anito-Cel Drives Durable Responses in R/R Multiple Myeloma
Author: Chris Ryan
Read The Full Article at OncLive25.
Find More Posts on Hemostasis Today.
-
Jun 19, 2025, 03:39ASH Recognizes 11 Hematologists for Transformative Contributions to Blood Disorder Research
-
Jun 17, 2025, 10:3025 Posts Not to Miss from EHA 2025
-
Jun 17, 2025, 05:10Recombinant ADAMTS13 Shows Superior Efficacy Over Plasma in Congenital TTP: A Paradigm Shift in Replacement Therapy - Blood Journals Portfolio
-
Jun 16, 2025, 17:00Hypoxia and Emergency Caesarean Deliveries Worsen Postpartum Outcomes in Sickle Cell Disease: New Insights from Perinatal Hemostasis Research
-
Jun 16, 2025, 10:42Jorge Cortes: The First Issue of Blood Global Hematology is Out
-
Jun 18, 2025, 15:49Abdul Mannan: Laboratory Alert - DOAC Interference in Heparin Monitoring
-
Jun 18, 2025, 08:19William Aird: Thrombocytosis - Know the difference, think before you refer
-
Jun 16, 2025, 18:24Talha Badar: TKI Selection Based on Mutation Profiles in CML at EHA 2025
-
Jun 16, 2025, 16:24Yelak Biru: Anito-Cel Drives Durable Responses in R/R Multiple Myeloma
-
Jun 15, 2025, 09:32Silent Threat: Underrated Risk of Thrombosis in IBD Outpatients Revealed by New Data - Thrombosis Update
-
Mar 6, 2025, 17:15Olympus Announces Launch of Single-Use Hemostasis Clip
-
Jun 18, 2025, 10:30Join "Where Cardiologists and Hematologists Meet" Session Organized by ESC and EHA
-
Jun 18, 2025, 09:01Nihar Desai: A 35 Year Old Man Presents with High Grade Fever...
-
Jun 17, 2025, 18:38Anastasia Conti: The European Hematology Association Congress Was Amazing
-
Jun 17, 2025, 17:07Mark Wildgust: Outstanding Results from the FLAIR Study Presented at EHA25
-
Jun 17, 2025, 15:03Hamayak Sisakian Announces ESC Heart Failure Center Accreditation
Jun 18, 2025, 15:49
Jun 18, 2025, 10:50
Jun 18, 2025, 09:01
Jun 18, 2025, 08:19
Jun 17, 2025, 18:38
Jun 17, 2025, 17:07
Jun 17, 2025, 15:03
Jun 17, 2025, 10:30
Jun 17, 2025, 06:55